EU expands approval of Alexion’s Soliris

28th August 2019 Uncategorised 0

At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.

More: EU expands approval of Alexion’s Soliris
Source: News